Insulet Corp (PODD) 43.52 $PODD
Shares of PODD Down 9.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:32AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 2 weeks, Insulet has returned 9.41% as of today's recent price of $42.55.
The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
M2 - Mon Apr 07, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z9ktc/the_us_diabetic) has announced the addition of the "The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology" report to their offering. The report titled The US Diabetic Devices Industry Outlook to 2018- Growth to be Led by Next Generation Technology presents a comprehensive analysis of the industry covering aspects including market size of SMBG devices, CGM systems and Insulin Delivery Devices market by revenue and market segmentation by product categories in SMBG devices and Insulin Delivery Devices market. The report also entails a detailed description on the recent trends and developments in the diabetic care devices market and competitive scenario of major players in the industry along with market share of major companies in SMBG devices and Insulin Delivery devices market. Key Topics Covered: 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it's Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market Segmentation, 2007-2013 3.1. By Blood Sugar Monitoring Devices, CGM Devices and Insulin Delivery Devices, 2010-2013 3.2. The US Self Blood Glucose Monitoring Devices Market Introduction 3.3. The US CGM Systems Market Introduction 3.4. The US Insulin Delivery Devices Market Size and Introduction, 2007-2013 3.5. Cause & Effect Relationship Analysis in the US Diabetic Care Devices Industry 4. Artificial Pancreas - The Ultimate Goal 5. Trends and Developments in the US Diabetic Care Devices Market 6. Prevalence of Diabetes across the US States 7. Patents Scenario in the US Diabetic Therapeutic Market 8. Strategic Partnerships and Acquisitions in the US Diabetic Market 9. The US Diabetic Care Devices Market SWOT Analysis 10. Company Profiles of Major Players in the US Diabetic Care Devices Market 11. The US Diabetic Care Devices Market Future Outlook and Projections, 2014-2018 12. The US Macro Economic Indicators: Current and Projections 12.1. Ageing Population in the US, 2007-2018 12.2. Consumer Healthcare Expenditure, 2007-2018 12.3. Diabetic Population in the US, 2007-2018 13. Appendix Companies Mentioned - Abbot laboratories - Dexcom inc - Insulet Corporation - LifeScan Inc - Medtronics - Novo Nordisk - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/3z...s_diabetic
Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14.
Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
Increased Earnings Estimates Seen for Insulet (PODD): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:31AM CDT
Insulet has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Insulet could be a solid choice for investors.
Concise Analysis of the International Insulin Pump Market
M2 - Tue Mar 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwx6kq/insulin_pump) has announced the addition of the "Concise Analysis of the International Insulin Pump Market" report to their offering. Insulin Pumps are gaining strong acceptance in the market as insulin delivery systems especially for type 1 diabetes patients. Insulin pumps are gaining a lot of attraction in United States and European countries. But due to high costs of insulin pumps it has still not able to penetrate successfully in emerging markets. If insulin pump cost declines then its market is expected to grow immensely. Number of insulin pump users is expected to grow with single digit CAGR for the period of 2013 to 2018. For the year 2013 United States is having the highest market share in insulin pump market worldwide. In terms of companies share Medtronic controls a major portion of insulin pump market globally. Insulin pump market is more than 4 Billion for the year 2013. Reimbursement plays an important factor for the growth of insulin pump in any country. 1. Overall Diabetes Population (2007 - 2018) 2. Type 1 Diabetes Population (2007 - 2018) 3. Type 2 Diabetes Population (2007 - 2018) 4. Insulin Pump Users (2007 - 2018) 5. Insulin Pump Market (2007 - 2018) 6. Reimbursement Policies of all the 16 Countries Key Topics Covered: 1. Executive Summary 2. Worldwide - Insulin Pump Users & Forecast 3. Worldwide - Insulin Pump Market & Forecast 4. Worldwide - Insulin Pump Market Share & Forecast 5. United States - Insulin Pump Analysis 6. Canada - Insulin Pump Analysis 7. Japan - Insulin Pump Analysis 8. Germany - Insulin Pump Analysis 9. Norway - Insulin Pump Analysis 10. Australia - Insulin Pump Analysis 11. Italy - Insulin Pump Analysis 12. Spain - Insulin Pump Analysis 13. France - Insulin Pump Analysis 14. Netherlands - Insulin Pump Analysis 15. Switzerland - Insulin Pump Analysis 16. Sweden - Insulin Pump Analysis 17. Israel - Insulin Pump Analysis 18. United Kingdom - Insulin Pump Analysis 19. Denmark - Insulin Pump Analysis 20. Finland - Insulin Pump Analysis 21. Worldwide Insulin Pump - Key Players Analysis 22. Growth Drivers 23. Challenges Companies Mentioned: - Animas Corporation (Acquired by Johnson & Johnson) - Insulet Corporation - Medtronic - Roche For more information visit http://www.researchandmarkets.com/research/ww...sulin_pump
Uptrend Call Working As Insulet Stock Rises 30.5% (PODD)
Comtex SmarTrend(R) - Wed Mar 12, 9:36AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 30.55% as of today's recent price of $48.12.
Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ
XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Earnings Estimates Moving Higher for Insulet (PODD): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:47AM CST
Insulet has decent short-term momentum plus a solid activity on the earnings estimate revision front as well
Global Continuous Glucose Monitoring (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) Market to 2020
M2 - Thu Mar 06, 11:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/k2xw8h/continuous) has announced the addition of the "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020" report to their offering. The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM. Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020. North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people. Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices. KEY BENEFITS - The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more - Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012 - Identification and analysis of key pockets of investment for CGM manufacturers - Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market - Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario - The report identifies and profiles key market participants that would drive innovation in the CGM market Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Continuous Glucose Monitors Market Overview Chapter 4 Continuous Glucose Monitoring Systems Market - By Devices Chapter 5 Continuous Glucose Monitoring System Market - By Application Chapter 6 Continuous Glucose Monitoring System Market - By Age Chapter 7 Cgm Systems Market By Geography Chapter 8 Company Profiles - Animas Corporation - Dexcom Inc. - Insulet Corporation - Medtronic Inc. - Novo Nordisk - Roche - Spring Health Solution Ltd - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/k2xw8h/continuous
Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 06, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/w77w6d/continuous) has announced the addition of the "Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals. The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market. According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS. The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products. Dexcom G4 Platinum CGM System market is expected to witness the fastest growth during the forecast period. FreeStyle Navigator that witnessed a decline in its market share in 2012 due to product recall from the U.S. market is anticipated to show significant growth during the forecast period due to expected launch of FreeStyle Navigator ll in 2014 in the U.S. market. Key Topics Covered: Preface Executive Summary Market Overview Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Abbott Laboratories - Bayer AG - Dexcom, Inc. - GlySens Incorporated - Insulet Corporation - Medtronic, Inc. - Nova Biomedical Corporation - Senseonics, Incorporated For more information visit http://www.researchandmarkets.com/research/w77w6d/continuous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
34.3% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Wed Mar 05, 9:08AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 34.31% as of today's recent price of $49.51.
Insulet Reports Fourth Quarter and Full Year 2013 Results
Marketwire - Thu Feb 27, 3:05PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Global Insulin Pumps Market 2014-2018: Animas, F. Hoffmann La Roche, Insulet & Medtronic Dominate the Industry
M2 - Wed Feb 26, 9:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/96vn4c/global_insulin) has announced the addition of the "Global Insulin Pumps Market 2014-2018: Animas, F. Hoffmann La Roche, Insulet & Medtronic Dominate the Industry" report to their offering. Electronic insulin pumps are fast becoming popular, effective, and preferred over traditional treatment methods for diabetes. As insulin pumps have recently come into prominence, new generations are beginning to see insulin pumps as a normal, conventional, and overall easier way to treat diabetes and are gaining patient acceptance. The pump allows blood sugar calculations to be done electronically and automatically, and presents less of a concern over constantly monitoring with a handheld device. In addition, the pump allows the user to eat and sleep comfortably because of its regulatory features. Thus, the use of insulin pumps has certainly made life easier for those using them. According to the report, one of the main drivers in this market is the increase in the diabetic population globally. Various factors responsible for diabetes include smoking, alcohol, obesity, and hypertension. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global Insulin Pumps market. Further, the report states that one of the major challenges faced by the market is the increase in the use of CAM. CAMs are cheaper alternatives to conventional medical care and their use is gaining prominence across the world. The key vendors dominating this market space are: - Animas Corp. - F. Hoffmann La Roche Ltd. - Insulet Corp. - Medtronic Inc. Other vendors mentioned in the report are: - Sooil Development Co. Ltd. - Tandem Diabetes Care Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product Type 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Product Comparison Snapshot 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/96...al_insulin
Lubega Predicts Ko Win
by Moses Mugalu - All Africa Global Media - Wed Feb 26, 12:33AM CST
Professional boxer Joseph Lubega has predicted a knockout victory over South African Ryno Liebenberg in their scheduled World Boxing Council International (WBC-I) light heavyweight title contest due this Saturday, March 1 in Johannesburg.
Insulet Has Returned 24.1% Since SmarTrend Recommendation (PODD)
Comtex SmarTrend(R) - Tue Feb 25, 4:49PM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 24.09% as of today's recent price of $45.74.
Insulet Corporation to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
Marketwire - Thu Feb 13, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2013 on February 27, 2014 after the close of the financial markets.
Shares of PODD Down 9.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:32AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 2 weeks, Insulet has returned 9.41% as of today's recent price of $42.55. The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
M2 - Mon Apr 07, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z9ktc/the_us_diabetic) has announced the addition of the "The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology" report to their offering. The report titled The US Diabetic Devices Industry Outlook to 2018- Growth to be Led by Next Generation Technology presents a comprehensive analysis of the industry covering aspects including market size of SMBG devices, CGM systems and Insulin Delivery Devices market by revenue and market segmentation by product categories in SMBG devices and Insulin Delivery Devices market. The report also entails a detailed description on the recent trends and developments in the diabetic care devices market and competitive scenario of major players in the industry along with market share of major companies in SMBG devices and Insulin Delivery devices market. Key Topics Covered: 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it's Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market Segmentation, 2007-2013 3.1. By Blood Sugar Monitoring Devices, CGM Devices and Insulin Delivery Devices, 2010-2013 3.2. The US Self Blood Glucose Monitoring Devices Market Introduction 3.3. The US CGM Systems Market Introduction 3.4. The US Insulin Delivery Devices Market Size and Introduction, 2007-2013 3.5. Cause & Effect Relationship Analysis in the US Diabetic Care Devices Industry 4. Artificial Pancreas - The Ultimate Goal 5. Trends and Developments in the US Diabetic Care Devices Market 6. Prevalence of Diabetes across the US States 7. Patents Scenario in the US Diabetic Therapeutic Market 8. Strategic Partnerships and Acquisitions in the US Diabetic Market 9. The US Diabetic Care Devices Market SWOT Analysis 10. Company Profiles of Major Players in the US Diabetic Care Devices Market 11. The US Diabetic Care Devices Market Future Outlook and Projections, 2014-2018 12. The US Macro Economic Indicators: Current and Projections 12.1. Ageing Population in the US, 2007-2018 12.2. Consumer Healthcare Expenditure, 2007-2018 12.3. Diabetic Population in the US, 2007-2018 13. Appendix Companies Mentioned - Abbot laboratories - Dexcom inc - Insulet Corporation - LifeScan Inc - Medtronics - Novo Nordisk - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/3z...s_diabetic
Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14. Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
Increased Earnings Estimates Seen for Insulet (PODD): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:31AM CDT
Insulet has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Insulet could be a solid choice for investors.
Concise Analysis of the International Insulin Pump Market
M2 - Tue Mar 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwx6kq/insulin_pump) has announced the addition of the "Concise Analysis of the International Insulin Pump Market" report to their offering. Insulin Pumps are gaining strong acceptance in the market as insulin delivery systems especially for type 1 diabetes patients. Insulin pumps are gaining a lot of attraction in United States and European countries. But due to high costs of insulin pumps it has still not able to penetrate successfully in emerging markets. If insulin pump cost declines then its market is expected to grow immensely. Number of insulin pump users is expected to grow with single digit CAGR for the period of 2013 to 2018. For the year 2013 United States is having the highest market share in insulin pump market worldwide. In terms of companies share Medtronic controls a major portion of insulin pump market globally. Insulin pump market is more than 4 Billion for the year 2013. Reimbursement plays an important factor for the growth of insulin pump in any country. 1. Overall Diabetes Population (2007 - 2018) 2. Type 1 Diabetes Population (2007 - 2018) 3. Type 2 Diabetes Population (2007 - 2018) 4. Insulin Pump Users (2007 - 2018) 5. Insulin Pump Market (2007 - 2018) 6. Reimbursement Policies of all the 16 Countries Key Topics Covered: 1. Executive Summary 2. Worldwide - Insulin Pump Users & Forecast 3. Worldwide - Insulin Pump Market & Forecast 4. Worldwide - Insulin Pump Market Share & Forecast 5. United States - Insulin Pump Analysis 6. Canada - Insulin Pump Analysis 7. Japan - Insulin Pump Analysis 8. Germany - Insulin Pump Analysis 9. Norway - Insulin Pump Analysis 10. Australia - Insulin Pump Analysis 11. Italy - Insulin Pump Analysis 12. Spain - Insulin Pump Analysis 13. France - Insulin Pump Analysis 14. Netherlands - Insulin Pump Analysis 15. Switzerland - Insulin Pump Analysis 16. Sweden - Insulin Pump Analysis 17. Israel - Insulin Pump Analysis 18. United Kingdom - Insulin Pump Analysis 19. Denmark - Insulin Pump Analysis 20. Finland - Insulin Pump Analysis 21. Worldwide Insulin Pump - Key Players Analysis 22. Growth Drivers 23. Challenges Companies Mentioned: - Animas Corporation (Acquired by Johnson & Johnson) - Insulet Corporation - Medtronic - Roche For more information visit http://www.researchandmarkets.com/research/ww...sulin_pump
Uptrend Call Working As Insulet Stock Rises 30.5% (PODD)
Comtex SmarTrend(R) - Wed Mar 12, 9:36AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 30.55% as of today's recent price of $48.12. Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ
ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register Earnings Estimates Moving Higher for Insulet (PODD): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:47AM CST
Insulet has decent short-term momentum plus a solid activity on the earnings estimate revision front as well
Global Continuous Glucose Monitoring (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) Market to 2020
M2 - Thu Mar 06, 11:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/k2xw8h/continuous) has announced the addition of the "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020" report to their offering. The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM. Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020. North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people. Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices. KEY BENEFITS - The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more - Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012 - Identification and analysis of key pockets of investment for CGM manufacturers - Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market - Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario - The report identifies and profiles key market participants that would drive innovation in the CGM market Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Continuous Glucose Monitors Market Overview Chapter 4 Continuous Glucose Monitoring Systems Market - By Devices Chapter 5 Continuous Glucose Monitoring System Market - By Application Chapter 6 Continuous Glucose Monitoring System Market - By Age Chapter 7 Cgm Systems Market By Geography Chapter 8 Company Profiles - Animas Corporation - Dexcom Inc. - Insulet Corporation - Medtronic Inc. - Novo Nordisk - Roche - Spring Health Solution Ltd - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/k2xw8h/continuous
Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 06, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/w77w6d/continuous) has announced the addition of the "Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals. The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market. According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS. The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products. Dexcom G4 Platinum CGM System market is expected to witness the fastest growth during the forecast period. FreeStyle Navigator that witnessed a decline in its market share in 2012 due to product recall from the U.S. market is anticipated to show significant growth during the forecast period due to expected launch of FreeStyle Navigator ll in 2014 in the U.S. market. Key Topics Covered: Preface Executive Summary Market Overview Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Abbott Laboratories - Bayer AG - Dexcom, Inc. - GlySens Incorporated - Insulet Corporation - Medtronic, Inc. - Nova Biomedical Corporation - Senseonics, Incorporated For more information visit http://www.researchandmarkets.com/research/w77w6d/continuous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
34.3% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Wed Mar 05, 9:08AM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 34.31% as of today's recent price of $49.51. Insulet Reports Fourth Quarter and Full Year 2013 Results
Marketwire - Thu Feb 27, 3:05PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Global Insulin Pumps Market 2014-2018: Animas, F. Hoffmann La Roche, Insulet & Medtronic Dominate the Industry
M2 - Wed Feb 26, 9:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/96vn4c/global_insulin) has announced the addition of the "Global Insulin Pumps Market 2014-2018: Animas, F. Hoffmann La Roche, Insulet & Medtronic Dominate the Industry" report to their offering. Electronic insulin pumps are fast becoming popular, effective, and preferred over traditional treatment methods for diabetes. As insulin pumps have recently come into prominence, new generations are beginning to see insulin pumps as a normal, conventional, and overall easier way to treat diabetes and are gaining patient acceptance. The pump allows blood sugar calculations to be done electronically and automatically, and presents less of a concern over constantly monitoring with a handheld device. In addition, the pump allows the user to eat and sleep comfortably because of its regulatory features. Thus, the use of insulin pumps has certainly made life easier for those using them. According to the report, one of the main drivers in this market is the increase in the diabetic population globally. Various factors responsible for diabetes include smoking, alcohol, obesity, and hypertension. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global Insulin Pumps market. Further, the report states that one of the major challenges faced by the market is the increase in the use of CAM. CAMs are cheaper alternatives to conventional medical care and their use is gaining prominence across the world. The key vendors dominating this market space are: - Animas Corp. - F. Hoffmann La Roche Ltd. - Insulet Corp. - Medtronic Inc. Other vendors mentioned in the report are: - Sooil Development Co. Ltd. - Tandem Diabetes Care Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product Type 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Product Comparison Snapshot 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/96...al_insulin
Lubega Predicts Ko Win
by Moses Mugalu - All Africa Global Media - Wed Feb 26, 12:33AM CST
Professional boxer Joseph Lubega has predicted a knockout victory over South African Ryno Liebenberg in their scheduled World Boxing Council International (WBC-I) light heavyweight title contest due this Saturday, March 1 in Johannesburg.
Insulet Has Returned 24.1% Since SmarTrend Recommendation (PODD)
Comtex SmarTrend(R) - Tue Feb 25, 4:49PM CST
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 24.09% as of today's recent price of $45.74. Insulet Corporation to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
Marketwire - Thu Feb 13, 3:15PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2013 on February 27, 2014 after the close of the financial markets.
